AIQ-931 (bioglutide)

aIQ-931 (Bioglutide)

The Next Generation in Metabolic Optimization

aIQ-931 is a first-in-class oral therapy designed to go beyond standard GLP-1 drugs. Where current treatments often sacrifice muscle or cause harsh GI side effects, aIQ-931 leverages a quadruple receptor agonist strategy, activating IGF-1, GLP-1, GIP, and glucagon receptors simultaneously.

This synergy creates a powerful metabolic reset:
GLP-1 + GIP → enhance insulin secretion, improve glucose control, and suppress appetite at the brain level.
Glucagon receptor → boosts fat oxidation and raises energy expenditure.
IGF-1 receptor → protects and preserves lean muscle mass while fat is being mobilized.

Unlike injectables, aIQ-931 is orally bioavailable, and is being researched as a once-daily, and able to cross the blood–brain barrier for central appetite modulation.

Clinical Proof

In Phase 2 clinical trials (13 weeks, 125 participants):
Up to 13.8% body weight reduction at the top dose (150 mg/day).
No muscle loss observed—a key differentiator from GLP-1 monotherapies.
Mild side effects only (nausea, diarrhea in <8%), with no severe adverse events.

These results position aIQ-931 as a superior alternative to single-pathway GLP-1 drugs like semaglutide and tirzepatide, especially for those prioritizing fat loss without compromising muscle integrity.

Why It Matters

Current GLP-1 agonists are effective but blunt tools—they drive appetite suppression and weight loss but often at the expense of lean tissue and overall metabolic resilience. aIQ-931 changes the game by:
Targeting multiple pathways at once for balanced, durable results.
Preserving muscle through IGF-1 activation while accelerating fat oxidation.
Enhancing compliance with a simple, oral, once-daily dose.

The Future of Obesity and Metabolic Care

aIQ-931 is advancing into Phase 3 global studies for obesity, diabetes, and metabolic syndrome—with potential applications in MASH (metabolic steatohepatitis) and related disorders. Early combination studies with semaglutide and tirzepatide suggest even greater impact when layered with current standards of care.

aIQ-931 at a Glance
Class: Quadruple receptor agonist (IGF-1, GLP-1, GIP, Glucagon)
Format: Oral, once-daily tablet
Outcomes: 13.8% bodyweight reduction in 13 weeks, preserved muscle mass
Safety: Mild, transient GI events; no severe side effects
Status: Completed Phase 2, moving into Phase 3 trials FOR RESEARCH USE ONLY

aIQ-931 delivers what the next generation of metabolic therapy demands: powerful fat loss, lean mass protection, and sustainable metabolic health without the compromises of today’s drugs.